J. Rigas

发表

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

L. Seymour, D. Gandara, M. Tsao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

H. Groen, Bruce E. Johnson, J. Rigas, 2016, The Lancet. Oncology.

Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Nonsmall Cell Lung Carcinoma (NSCLC): A Randomized Phase II Trial

J. Rigas, L. Nguyen, V. Hirsh, 2007, American journal of clinical oncology.

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.

Devin K. Schweppe, J. Rigas, S. Gerber, 2013, Journal of proteomics.

Docetaxel in stage III and IV non-small cell lung cancer.

J. Rigas, J R Rigas, 1995, European journal of cancer.

New Oral Chemotherapeutic Agents for Lung Cancer

J. Rigas, E. Bengtson, 2012, Drugs.

Recent advances in cancer chemotherapy.

J. Rigas, J. Pipas, D. Ornstein, 1999, Academic radiology.

Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period

J. Rigas, C. Kessler, G. Merli, 2003 .

Docetaxel in the treatment of esophageal cancer.

J. Rigas, K. Dragnev, J. Bubis, 2005, Seminars in oncology.

Expression of apoptosis-related proteins and response to chemoradiotherapy and prognosis in esophageal cancer

J. Rigas, R. Rosell, A. Eastman, 2000, Revista de Oncología.

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

M. Kris, V. Rusch, P. McCormack, 1993, The Annals of thoracic surgery.

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

H. Groen, J. Rigas, D. Planchard, 2015 .

O-107 Adjuvant targeted therapy in unresectable lung cancer: The results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI)

J. Rigas, R. Winston, J. W. Smith, 2003 .

A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10

L. Seymour, R. Livingston, K. Ding, 2004 .

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

E. Dmitrovsky, J. Rigas, G. Gordon, 2012, Chemotherapy.

Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.

J. Rigas, K. Leopold, J. Rathmann, 1999, Seminars in radiation oncology.

A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10.

L. Seymour, R. Livingston, K. Ding, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma

J. Rigas, C. Fadul, L. Cromwell, 2005, Journal of Neuro-Oncology.

A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history

M. Berger, J. Rigas, F. Shepherd, 2007 .

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

J. Rigas, R. Perez-soler, G. Clark, 2003 .

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

J. Rigas, K. Dragnev, M. Schuster, 2011, Expert opinion on biological therapy.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials.

M. Kris, J. Rigas, F. Shepherd, 2001, Seminars in oncology.

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

L. Seymour, R. Livingston, M. Tsao, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic phenotypes of retinoic acid and the risk of lung cancer.

M. Kris, R. Warrell, V. Miller, 1996, Cancer research.

Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).

N. Martini, R. Ginsberg, V. Miller, 1995, Lung cancer.

Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer

K. Kelly, J. Rigas, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer.

J. Rigas, P. Lara, 2005, Lung cancer.

O-58 Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10)

L. Seymour, R. Livingston, K. Ding, 2003 .

SINGLE-AGENT DOCETAXEL IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG CANCER

J. Rigas, 1997 .

Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.

M. Kris, R. Warrell, J. Rigas, 1993, Journal of the National Cancer Institute.

Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer.

R. Warrell, H. Scher, J. Rigas, 1994, Cancer research.

Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.

M. Kris, R. Warrell, J. Rigas, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

P-238 Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresetable non-small cell lung cancer (NSCLC)

L. P. Meyers, P. J. Hoopes, J. Rigas, 2003 .

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer

J. Rigas, A. Dowlati, L. Leopold, 2005 .

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

M. Kris, V. Miller, J. Rigas, 1995, Lung cancer.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

L. Seymour, R. Livingston, K. Ding, 2007, Lung cancer.

Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

J. Rigas, 2001, Seminars in oncology.

Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study

P. Wen, R. Govindan, J. Rigas, 2008 .

9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.

R. Warrell, J. Rigas, W. Miller, 1995, Blood.

Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.

J. Rigas, D. Ornstein, A. Nervi, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Regression of metastatic non-small cell lung cancer with low molecular weight heparin.

J. Rigas, L. Zacharski, J. Loynes, 2002, Thrombosis and haemostasis.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J. Rigas, R. Perez-soler, G. Clark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapy with erlotinib prolongs survival in NSCLC

J. Rigas, K. Dragnev, 2005 .

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

G. Demetri, A. Saven, J. Rigas, 2001, British Journal of Cancer.

Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?

J. Rigas, 1998, Seminars in oncology.

KRAS and EGFR Results From EBUS Evaluation of Mediastinal Adenopathy

J. Rigas, W. Nugent, K. Dragnev, 2011 .

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

L B Sheiner, A Riva, P M Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

268 Daily paclitaxel and thoracic radiation for the treatment of stage II-IIIB NSCLC

J. Rigas, W. Eaton, L. H. Maurer, 1997 .

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer

M. Kris, V. Miller, J. Rigas, 1997, Cancer Chemotherapy and Pharmacology.

Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.

M. Kris, R. Warrell, J. Rigas, 1992, Cancer research.

Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer.

J. Rigas, A. Olszanski, 2000, Clinical lung cancer.

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

R. Figlin, F. Khuri, J. Rigas, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

M. Kris, R. Warrell, V. Miller, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The retinoids and cancer prevention mechanisms.

E. Dmitrovsky, J. Rigas, K. Dragnev, 2000, The oncologist.

Bexarotene and erlotinib for aerodigestive tract cancer.

E. Dmitrovsky, J. Rigas, K. Dragnev, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.

M. Nørgaard, N. Shire, S. Hamilton-Dutoit, 2021, Cancer epidemiology.

Pemetrexed in advanced non-small-cell lung cancer

J. Rigas, K. Dragnev, A. Fuld, 2010, Expert opinion on pharmacotherapy.

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

E. Dmitrovsky, C. Henschke, F. Hirsch, 2002, Lung cancer.

Taxane-platinum combinations in advanced non-small cell lung cancer: a review.

J. Rigas, 2004, The oncologist.

Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer

J. Rigas, K. Dragnev, M. Turk, 2013, Lung.

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

J. Rigas, F. Shepherd, M. Smylie, 2010, Clinical Cancer Research.

Uncovering novel targets for cancer chemoprevention.

S. Kitareewan, E. Dmitrovsky, J. Rigas, 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

E. Dmitrovsky, J. Rigas, J. Kurie, 2011, Cancer Prevention Research.

Nonclassical retinoids and lung carcinogenesis.

E. Dmitrovsky, J. Rigas, K. Dragnev, 2005, Clinical lung cancer.

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.

J. Rigas, K. Dragnev, 2005, The oncologist.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Robert Livingston, Lesley Seymour, Ming-Sound Tsao, 2005, The New England journal of medicine.

Modulation of all-trans retinoic acid pharmacokinetics by liarozole

M. Kris, E. Venkatraman, R. Warrell, 2004, Cancer Chemotherapy and Pharmacology.

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

H. Dai, N. Shire, M. Schabath, 2019, Cancer management and research.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

J. Rigas, K. Dragnev, G. Tsongalis, 2013, Cancer treatment reviews.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2019, Future oncology.

Hypertensive crisis following meperidine administration and chemoembolization of a carcinoid tumor.

J. Rigas, C. Beaver, L. M. Balestrero, 2000, Archives of internal medicine.

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

J. Rigas, R. Perez-soler, Tianhong Li, 2010, Lung cancer.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

J. Rigas, J. Bérille, R. Bruno, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.

L. Seymour, R. Livingston, K. Ding, 2005, Lung cancer.

New chemotherapeutic agents for non-small cell lung cancer.

M. Kris, V. Miller, J. Rigas, 1995, Chest.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers

E. Dmitrovsky, J. Rigas, W. Nugent, 2004, Clinical Cancer Research.

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

M. Kris, J. Rigas, P. Francis, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.

B. Han, Changli Wang, J. Rigas, 2013, Journal of thoracic disease.

Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

Jawed Fareed, J. Rigas, C. Kessler, 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.

J. Rigas, F. Fossella, 1999, Seminars in oncology.

Randomized Phase II Trial Comparing Two Versus Three Doses of Ondansetron When Used in Combination with Dexamethasone in Patients Receiving Cisplatin ≥100 mg/m2

M. Kris, J. Rigas, K. Pisters, 1994, American journal of clinical oncology.

Phase II trial of a 75‐mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non‐small cell lung cancer

M. Kris, E. Venkatraman, V. Miller, 1995, Cancer.

Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer.

J. Rigas, T. Ahles, D. Hann, 2001, Journal of pain and symptom management.

Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.

M. Kris, T. Chou, V. Miller, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule

M. Kris, R. Warrell, V. Miller, 2004, Cancer Chemotherapy and Pharmacology.

A Dose Escalation Trial of Biweekly Docetaxel and Gemcitabine with Filgrastim or Pegfilgrastim for the Treatment of Patients with Advanced Solid Tumors

J. Rigas, K. Dragnev, J. Pipas, 2010, Chemotherapy.

Lung Cancer in a U.S. Population with Low to Moderate Arsenic Exposure

M. Karagas, A. Andrew, J. Rigas, 2009, Environmental health perspectives.

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.

M. Kris, V. Miller, J. Rigas, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.

L. Seymour, R. Livingston, K. Ding, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

J. Rigas, K. Prabhash, M. Schuster, 2010 .

Modulation of apoptosis signaling pathways and cell cycle regulation.

J. Rigas, A. Eastman, 1999, Seminars in oncology.

The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancer.

J. Rigas, K. Dragnev, W. J. Petty, 2002, Clinical lung cancer.

Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment.

J. Rigas, W. Nugent, P. Hammerness, 1997, The Annals of thoracic surgery.

The ENABLE III randomized controlled trial of concurrent palliative oncology care.

M. Hegel, T. Tosteson, J. Rigas, 2014 .

ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2017 .

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark

M. Nørgaard, N. Shire, S. Hamilton-Dutoit, 2023, PloS one.

Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 cases

Mary C. Schwab, J. Rigas, G. Tsongalis, 2013, Diagnostic cytopathology.

A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer

E. Dmitrovsky, J. Rigas, W. Nugent, 2007, Clinical Cancer Research.

Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study

P. Wen, R. Govindan, J. Rigas, 2007 .

Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.

J. Rigas, S. Karve, R. Kelly, 2019, Journal of oncology practice.

Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial.

J. Rigas, K. Prabhash, M. Schuster, 2010 .

Phase I Clinical and Pharmacological Study of Chloroquinoxaline Sulfonamide 1

M. Kris, R. Warrell, J. Rigas, 2007 .

Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10.

L. Seymour, R. Livingston, K. Ding, 2006, Journal of Clinical Oncology.

A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.

J. Rigas, K. Dragnev, S. Bhatt, 2018, Journal of thoracic disease.

Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

J. Rigas, R. Perez-soler, Tianhong Li, 2008 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC)

E. Dmitrovsky, J. Rigas, W. Nugent, 2005 .

A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

F. Khuri, R. Herbst, J. Rigas, 2005 .

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

P. Wen, L. Deangelis, R. Govindan, 2015, Cancer.

Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112

J. Rigas, K. Dragnev, H. Ghazal, 2008 .

O-098 Survival equivalence of non-platinum-based and platinum-basedchemotherapy for advanced non-small cell lung cancer (NSCLC): The results of a multicenter internet-based Phase III randomized study (D0112)

J. Rigas, K. Dragnev, H. Ghazal, 2005 .

PD4-1-5: Docetaxel, carboplatin and thoracic radiotherapy in unresectable stage III non-small cell lung cancer (NSCLS): A safety report of the first 100 patients treated with this concurrent chemoradiation as part of a multicenter web-based trial, D0410

J. Rigas, K. Dragnev, D. Zimmerman, 2007 .

The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high‐dose cisplatin

M. Kris, J. Rigas, K. Pisters, 1994, Cancer.